Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 34


Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.

Catalano MG, Pugliese M, Gallo M, Brignardello E, Milla P, Orlandi F, Limone PP, Arvat E, Boccuzzi G, Piovesan A.

Int J Endocrinol. 2016;2016:2930414.


A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.

Nilubol N, Merkel R, Yang L, Patel D, Reynolds JC, Sadowski SM, Neychev V, Kebebew E.

Clin Endocrinol (Oxf). 2016 Jul 9. doi: 10.1111/cen.13154.


Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.

Shi X, Li M, Cui M, Niu C, Xu J, Zhou L, Li W, Gao Y, Kong W, Cui J, Hu J, Jin H.

Am J Cancer Res. 2016 Feb 15;6(3):600-14.


Generation of Novel Thyroid Cancer Stem-Like Cell Clones: Effects of Resveratrol and Valproic Acid.

Hardin H, Yu XM, Harrison AD, Larrain C, Zhang R, Chen J, Chen H, Lloyd RV.

Am J Pathol. 2016 Jun;186(6):1662-73. doi: 10.1016/j.ajpath.2016.02.003.


Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.

Cha HY, Lee BS, Chang JW, Park JK, Han JH, Kim YS, Shin YS, Byeon HK, Kim CH.

Cancer Lett. 2016 Mar 1;372(1):65-74. doi: 10.1016/j.canlet.2015.12.016.


Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA).

Xu Y, Xu D, Zhu SJ, Ye B, Dong JD, Zhang YL, Zhang Y.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8291-7.


Antiepileptic drugs alter the expression of placental carriers: An in vitro study in a human placental cell line.

Rubinchik-Stern M, Shmuel M, Eyal S.

Epilepsia. 2015 Jul;56(7):1023-32. doi: 10.1111/epi.13037.


The Beneficial Effects of Valproic Acid in Thyroid Cancer Are Mediated through Promoting Redifferentiation and Reducing Stemness Level: An In Vitro Study.

Haghpanah V, Malehmir M, Larijani B, Ahmadian S, Alimoghaddam K, Heshmat R, Ghavamzadeh A, Adabi K, Ghaffari SH.

J Thyroid Res. 2014;2014:218763. doi: 10.1155/2014/218763.


Sodium valproate-related hyperammonaemic encephalopathy.

Pegg EJ, Zaman F.

BMJ Case Rep. 2014 Apr 10;2014. pii: bcr2014203899. doi: 10.1136/bcr-2014-203899.


Valproic acid downregulates NF-κB p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line.

Schwertheim S, Worm K, Schmid KW, Sheu-Grabellus SY.

Horm Metab Res. 2014 Mar;46(3):181-6. doi: 10.1055/s-0034-1367043.


Repositioning therapy for thyroid cancer: new insights on established medications.

Kushchayeva Y, Jensen K, Burman KD, Vasko V.

Endocr Relat Cancer. 2014 Jun;21(3):R183-94. doi: 10.1530/ERC-13-0473. Review.


Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.

Cha HY, Lee BS, Kang S, Shin YS, Chang JW, Sung ES, Kim YS, Choi JW, Kim JH, Kim CH.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S716-24. doi: 10.1245/s10434-013-3232-y.


Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.

Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S.

Ann Oncol. 2013 Sep;24(9):2256-61. doi: 10.1093/annonc/mdt177.


Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.

Maggisano V, Puppin C, Celano M, D'Agostino M, Sponziello M, Micali S, Navarra M, Damante G, Filetti S, Russo D.

Endocrine. 2014 Feb;45(1):148-52. doi: 10.1007/s12020-013-9972-4.


Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.

Coulter DW, Walko C, Patel J, Moats-Staats BM, McFadden A, Smith SV, Khan WA, Bridges AS, Deal AM, Oesterheld J, Davis IJ, Blatt J.

Anticancer Drugs. 2013 Apr;24(4):415-21. doi: 10.1097/CAD.0b013e32835dc7c5.


Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas.

Micali S, Maggisano V, Cesinaro A, Celano M, Territo A, Reggiani Bonetti L, Sponziello M, Migaldi M, Navarra M, Bianchi G, Filetti S, Russo D.

J Endocrinol. 2013 Feb;216(2):125-33. doi: 10.1530/JOE-12-0495. Review.


Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma.

Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ.

Cell Biochem Biophys. 2013 Mar;65(2):203-10. doi: 10.1007/s12013-012-9419-1.


The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress.

Klubo-Gwiezdzinska J, Jensen K, Bauer A, Patel A, Costello J Jr, Burman KD, Wartofsky L, Hardwick MJ, Vasko VV.

J Endocrinol. 2012 Aug;214(2):207-16. doi: 10.1530/JOE-12-0081.


Novel molecular targeted therapies for refractory thyroid cancer.

Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE.

Head Neck. 2012 May;34(5):736-45. doi: 10.1002/hed.21755. Review.


Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.

Mitmaker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, Clark OH, Shen WT.

Surgery. 2011 Apr;149(4):504-11. doi: 10.1016/j.surg.2010.10.007.

Items per page

Supplemental Content

Loading ...
Support Center